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Finasteride is a potent and specific inhibitor of the 5α-reductase enzyme in men. Clinical studies have shown that
finasteride 1mg/day is effective for promoting hair growth in men with male pattern hair loss. However, there is a concern
about the use of finasteride, especially in young fertile patients, because of its action on testosterone metabolism. This paper
describes 3 cases of young patients who had very poor seminal quality during finasteride treatment (1 mg/day), and their
seminal quality greatly improved after cessation of finasteride treatment. Two of them presented with a left varicocele and
the other was obese. We hypothesize that finasteride may not dramatically change the spermatogenesis process in healthy
men, but in patients with conditions related to infertility, an amplification of the negative influence of finasteride could
occur. Future studies should be done to clarify the extent of the effect of finasteride in patients fertility problems.
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Finasteride is a potent and specific
inhibitor of the 5α-reductase enzyme.1
It inhibits the conversion of testoster-
one to dihydrotestosterone (DHT).2
Dihydrotestosterone is the most potent
androgen, and its level directly affects
prostate development.
It is known that the use of 5α-re-
ductase enzyme inhibitors like
finasteride, when administered at 5 mg/
day, reduce the prostatic size around
20% to 30%.3 Finasteride has been
used for the treatment of benign pros-
tate hyperplasia. Clinical studies have
shown that finasteride 1 mg/day is also
effective in promoting hair growth in
men with male pattern hair loss.4
There has been a concern regarding
the use of finasteride, especially in
young patients, because of its action on
testosterone metabolism. Overstreet et
al. (1999) demonstrated in a prospec-
tive clinical trial that treatment with
finasteride 1 mg/day does not affect
spermatogenesis or the spermatozoa
production in young healthy men.1
However, Kinniburg et al. (2001)
showed that the use of finasteride pro-
motes a significant reduction of the se-
rum level of DHT, decrease of the
plasma seminal volume, and the sup-
pression of gonadotropin secretion, re-
sulting in impairment of spermatogen-
esis.2 O’Donnel et al. (1999) showed in
an animal model that the use of
finasteride promoted partial inhibition
of spermatogenesis.2 A Medline review
searching with the key words
finasteride and fertility produced 3 pa-
pers related to the positive influence of
finasteride on the fertility, but none of
them were performed with humans.
Cukierski et al. (1991) and Wise et al.
(1991) showed that in rats the adminis-
tration of 80 mg/kg/day of finasteride
decreased fertility.5,6 According to
Iguer-Ouada et al. (1997), finasteride (1
mg/kg) promoted an increase in sperm
concentration and decrease in volume
of prostatic secretion in male beagle
dogs.7 The effects on the fertility of a
long period of finasteride treatment are
not completely defined.
The aim of this study was describe
3 cases of young male patients who
consulted for infertility and showed se-
vere decrease of spermatogenesis dur-
ing finasteride treatment (1 mg/day).
CASE REPORT
Patient 1
A male patient, aged 31 years, pre-
sented for fertility evaluation. He and his
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wife had been trying to achieve preg-
nancy for 10 months. He had a varic-
ocele diagnosed 10 years earlier, and at
that time, he had not been surgically
treated because he had had a normal
seminal analysis. He had been on
finasteride 1 mg/day for 2 years because
of hair loss. His physical exam showed
a normal testis and a moderate left vari-
cocele. His first seminal analysis showed
8.2 million sperm/mL with 70% motil-
ity, and 7% normally shaped spermato-
zoa, according the Kruger criteria.8 The
second analysis showed 7 million sperm/
mL, with 57% motility and 10% of nor-
mal shape. Before a varicocele repair, the
patient was asked to interrupt finasteride
for 4 months. After that period, a new
seminal analysis showed a total concen-
tration of 50 million spermatozoa, with
70% motility and 19% of normal shape.8
Patient 2
A male patient, aged 33 years, was
referred for fertility evaluation. He and
his wife had been trying to achieve a
pregnancy for 6 months. He had been on
finasteride 1 mg/day for 1 year because
of hair loss. At the physical exam, the
testes were normal, but there were small
cysts in the head of the epididymis bi-
laterally and a moderate-sized left vari-
cocele. His seminal analysis showed a to-
tal sperm concentration of 15 million
spermatozoa/ml with 20% motility and
17% normally shaped spermatozoa/ml.8
Finasteride was interrupted for 3 months,
and a new seminal analysis showed a to-
tal concentration of 43 million sperma-
tozoa/ml with 42% motility and 15% of
normal shape.8
Patient 3
An obese male patient, aged 32
years, was referred for infertility evalu-
ation. The couple had been trying to
achieve pregnancy for 6 months. He
had been on finasteride 1 mg/day for
more than 1 year. There were no abnor-
malities in his physical exam. His first
seminal analysis presented total con-
centration of 970,000 spermatozoa/ml
with 30% motility and 16% normally
shaped spermatozoa/ml.8 A second exam
showed a total concentration of 360
thousand spermatozoa/ml with 20%
motility and 15% of normal shape.
Finasteride treatment was interrupted,
and after 3 months a seminal analysis
showed a total concentration of 10 mil-
lion spermatozoa/ml with 60% motil-
ity and 22% of normal shape.8 Another
seminal analysis was done 3 months
later and showed total concentration of
7.2 million spermatozoa/ml with 50%
motility and 22% of normal shape.
DISCUSSION
Finasteride has been used for the
treatment of benign prostate
hyperplasy and male pattern hair loss.
Many young men in their fertile age
have used this drug for long periods
because of hair loss.
Finasteride inhibits 5α-reductase,
preventing the transformation of testo-
sterone to dihydrotestosterone, which
could cause a negative influence on
the sperm production. O’Donnell et al.
(1999) showed a negative impact of
finasteride in rat spermatogenesis.9
However, Overstreet et al. (1999) re-
ported that finasteride 1 mg/day did
not affect spermatogenesis, seminal
production, sperm motility, or sperm
morphology in young healthy men.1
The 3 patients reported on this pa-
per showed abnormal sperm concentra-
tion and motility while using
finasteride 1 mg/day. Those alterations
were completely reversed (patient 1
and 2) or improved (patient 3) 3 or 4
months after the interruption of
finasteride treatment. The first patient
had a history of having a normal semi-
nal analysis 10 years before when he
had been seen by a urologist to evalu-
ate the need for a varicocele repair,
which was not done at that time. In
case 3 there was a dramatic improve-
ment from less than 1 million sperm/
mL to 10 million sperm/mL 3 months
after cessation of finasteride treatment.
Although the improved sperm concen-
tration was still abnormal, it permitted
the couple to be treated with intrauter-
ine insemination instead of with intra-
cytoplasmic sperm injection.
It is interesting to stress that 2 pa-
tients had a varicocele and the third one
was obese. We hypothesize that perhaps
finasteride does not dramatically
change the spermatogenesis process in
healthy men as shown by Overstreet et
al. (1999), but in patients with other
problems contributing to infertility, the
negative influence of finasteride noted
by others might be amplified. Future
studies should be done to clarify the
extent of the effect of finasteride in pa-
tients with fertility problems.
RESUMO
GLINA S e col. Infertilidade masculina
associada ao uso de finasterida.
Rev. Hosp. Clín. Fac. Med. S.
Paulo 59 (4):203-205, 2004.
A finasterida é um potente e espe-
cífico inibidor da enzima 5α-redutase
em homens. Estudos clínicos demons-
traram que finasterida 1mg/dia diminui
a progressão da queda e aumenta o
crescimento do cabelo em homens que
sofrem de queda de cabelo hereditária.
Por sua influência no metabolismo dos
andrógenos existe uma preocupação a
respeito do seu uso, principalmente em
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pacientes em idade fértil. Neste traba-
lho são descritos 3 casos de pacientes
jovens, que apresentaram piora do
espermograma durante o uso continu-
ado de finasterida 1mg revertida após
a suspensão do mesmo. Dois deles ti-
nham varicocele unilateral e o tercei-
ro era obeso. Aparentemente o trata-
mento com finasterida promoveu alte-
ração significativa na qualidade semi-
nal. Pode-se especular que talvez a
finasterida por si só não traga altera-
ção para a espermatogênese como re-
portado por Overstreet et al. (1999),
mas que em pacientes de risco com
possíveis causas de infertilidade asso-
ciadas, possa ocorrer a amplificação da
influência deletéria da finasterida. Es-
tudos futuros devem ser realizados
para esclarecer a influência da finaste-
rida nestes pacientes.
UNITERMOS: Finasterida. Ferti-
lidade. Espermatogênese. Esperma-
tozóide. Parâmetros seminais.
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